SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as traders discuss a potential short squeeze and a possible buyout by Coinbase ($COIN), though the latter remains unconfirmed. The community is weighing the stock's undervaluation against concerns about profitability and past ties to China, with some pointing to Robinhood's earnings as a positive sign for the sector. Bullish sentiment is countered by bearish arguments about share dilution and unfavorable chart patterns, leading to a divided discussion on the stock's near-term potential.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions around its recent earnings call, with community members debating the company's financial health and future prospects. While some bulls express confidence in IONQ's long-term potential and government contracts, bears raise concerns about cash burn, revenue, and valuation. The community is also closely watching for any further news or developments in the quantum computing sector.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending as investors anticipate upcoming earnings and a potential 

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anxiously await upcoming earnings, with many anticipating strong results fueled by the Alani Nu acquisition and expanded distribution with Pepsi. The community is debating the potential impact of macro events like tariffs, while also closely watching technical indicators and expecting significant price movement post-earnings release. Bullish sentiment remains strong, with many expressing long-term confidence in CELH's growth potential.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending amid discussions about its recent earnings beat but subsequent stock drop, with the community debating the reasons behind the disconnect, including concerns about future guidance and the potential impact of AI on its business model; some investors view the dip as a buying opportunity, citing strong fundamentals and long-term growth potential, while others remain cautious about valuation and competition.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer ($ICP) is trending as it attempts to break through a significant resistance level around $6.20, with community members closely watching for a potential breakout and surge toward $7. Bullish sentiment is fueled by discussions around its advanced decentralized cloud ecosystem and potential for large-scale adoption, while some traders note its pump-and-dump tendencies.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap's stock is trending after hours due to a combination of a Q3 earnings beat, a $500 million stock buyback program, and a $400 million AI partnership with Perplexity. The community is buzzing with excitement over the potential for a short squeeze and the company's future prospects. Some investors, however, remain skeptical about Snap's ability to sustain gains and achieve profitability.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation of a potential buyout, fueled by a bidding war between PFE and NVO for Metsera, a company with a less advanced pipeline. The community is discussing the possibility of VKTX being an attractive acquisition target due to its promising weight loss drug and MASH asset, with some suggesting that a deal could be worth billions. Community members are discussing a potential bidding war which has some highlighting VKTX's de-risked position due to clinical trials.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

$SWEAT is trending amid community excitement about its potential, with many highlighting its association with a health-focused app that rewards users for physical activity. Discussions center on its long-term prospects and staking opportunities. Some users anticipate a future bull run, viewing it as a promising project despite its current low price.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft ($LYFT) is trending as investors discuss the ride-sharing company's potential acquisition, with Amazon being a highlighted suitor, and analysts predicting a buyout within 6-9 months; also, positive Q3 earnings and autonomous vehicle partnerships continue to fuel community optimism, though government shutdown concerns create uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates

CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of +13.95% and +3.65%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.</li><li>The company’s late-stage HOPE-3 trial for Deramiocel remains on track, with topline data expected later this quarter and plans to resubmit its biologics license application afterward.</li><li>Retail traders on Stocktwits voiced optimism that Deramiocel could become the next breakthrough for patients after Sarepta’s setback.</li></ul>Retail chatter around Capricor Therapeutics spiked on Monday after the biotech company published a peer-reviewed study in Biomedicines detailing the mechanism of action and potency assay for its investigational cell therapy, Deramiocel, which is being developed to treat Duchenne muscular dystrophy (DMD).<h2 class="st-heading-2">Peer-Reviewed Study Highlights</h2>The new publication described how Deramiocel’s active components, which are cardiosphere-derived cells (CDCs), suppress fibrosis-related genes such as collagen I and III in human fibroblasts. This anti-fibrotic mechanism supports the therapy’s potential to slow disease progression in DMD.The analysis validated the reliability of a potency&nbsp;test&nbsp;used to demonstrate batch-to-batch consistency of the product. Capricor said the data is in line with more than four years of clinical data showing the cardiac condition has stabilized in patients.<h2 class="st-heading-2">Late-Stage Progress</h2>Capricor CEO Linda Marban said the new assay strengthens confidence in Deramiocel’s biological profile and the company’s ability to ensure consistent quality as it moves deeper into late-stage trials.Deramiocel is in development in the Phase 3 HOPE-3 trial, with data topline anticipated in the middle of the fourth quarter. The company will resubmit the biologics license application (BLA) to the FDA after the data are available.<h2 class="st-heading-2">Stocktwits Traders See Capricor As The Next Hope For DMD Patients</h2>On Stocktwits, retail sentiment for Capricor was ‘extremely bullish’ amid a 565% surge in 24-hour message volume.One user said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-therapeutics-stock-crashes-after-hours-on-dmd-trial-failure-q3-print/cL2FDdvR3Ce">Sarepta’s trial setback</a> was unfortunate for Duchenne muscular dystrophy patients, adding that “these kids deserve better” and that meaningful progress will only come once the FDA approves Capricor’s therapy.&nbsp;<stembedurl>https://stocktwits.com/Pennyforyourbuck/message/634795350</stembedurl>Another user wrote that Capricor now stands as “the last DMD company alive,” predicting that its Phase 3 trial will be “epic” and could send the stock soaring.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/634792751</stembedurl><a href="https://stocktwits.com/symbol/CAPR">Capricor’s stock</a> has declined 56% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback

Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.

Equity

Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last?

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Oct. 28, 2025...

Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains?

Capricor (CAPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR Capricor Therapeutics, Inc. Sued for Securities Law Violations...

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR Faruqi & Faruqi Reminds Capricor Investors of the Pending...

Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates

Quanterix (QTRX) delivered earnings and revenue surprises of -14.63% and -12.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CAPR News

CAPRCapricor Therapeutics Inc